FDA has released information it collected from judicial diversion and counterfeiting cases investigated by the Agency’s Office of Criminal Investigations (OCI) from 2003-2008. The data was reviewed and analyzed by the Center for Drug Evaluation and Research (CDER).
CDER highlights three examples of criminal drug schemes investigated by OCI and evaluates the types of drug products and the trade of the suspects involved. The evaluation covers: ● brokers ● doctors ● importers ● manufacturers ● pharmacists ● pharmacies ● repackagers ● sales representatives ● wholesalers ● practitioners ● consumer/patients ● truck drivers, and ● shippers. The report and analysis was released by the agency in late September, 2011.
[Editor’s note: The supply chain consortium Rx-360 produced a summary of the report – a link is provided below.]